Mona Ashiya Sells 202,146 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 202,146 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $54.29, for a total transaction of $10,974,506.34. Following the sale, the director now directly owns 208,742 shares of the company’s stock, valued at approximately $11,332,603.18. This represents a 49.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Mona Ashiya also recently made the following trade(s):

• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total transaction of $4,529,259.90.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON opened at $52.41 on Friday. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -13.17 and a beta of 0.73. The firm has a fifty day moving average price of $56.62 and a 200 day moving average price of $55.94. Disc Medicine, Inc. has a fifty-two week low of $25.60 and a fifty-two week high of $68.86.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.08. As a group, research analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Institutional Investors Weigh In On Disc Medicine

A number of hedge funds have recently made changes to their positions in IRON. FMR LLC increased its stake in Disc Medicine by 358.7% in the 4th quarter. FMR LLC now owns 1,866,248 shares of the company’s stock worth $118,320,000 after acquiring an additional 1,459,434 shares during the last quarter. Janus Henderson Group PLC increased its position in Disc Medicine by 62.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after purchasing an additional 467,988 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Disc Medicine by 23.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock worth $88,421,000 after purchasing an additional 262,690 shares during the last quarter. State Street Corp raised its stake in Disc Medicine by 39.7% during the third quarter. State Street Corp now owns 827,910 shares of the company’s stock valued at $40,683,000 after purchasing an additional 235,115 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Disc Medicine during the fourth quarter valued at $5,579,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IRON has been the topic of several analyst reports. TD Cowen started coverage on Disc Medicine in a research report on Thursday, February 27th. They set a “buy” rating on the stock. Scotiabank boosted their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. Morgan Stanley restated an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. Wedbush reiterated an “outperform” rating and issued a $90.00 price target (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Disc Medicine currently has a consensus rating of “Buy” and a consensus price target of $89.10.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.